查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602226

病毒载体和质体DNA 製造市场：按类型、细胞株、转染、适应症、工作流程、应用、最终用户 - 2025-2030 年全球预测

Viral Vector & Plasmid DNA Manufacturing Market by Type (Plasmid DNA, Viral Vector), Cell Line (In-vitro, In-Vivo), Transfection, Indication, Workflow, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

病毒载体质体DNA製造市场2023年估值为15亿美元，预计到2024年将达18.8亿美元，复合年增长率为25.34%，预计到2030年将达到73.2亿美元。

在基因治疗、疫苗和细胞疗法需求不断增长的推动下，病毒载体和质体DNA 製造业在生物製药中发挥着至关重要的作用。此领域包括病毒载体的生产（将遗传物质传递到细胞中的工具）和质体DNA（作为基因治疗和 DNA 疫苗生产的模板）。由于遗传疾病和癌症治疗的兴起，尤其是最近 COVID-19 引起的对疫苗开发的关注，这种製造变得至关重要。应用范围包括基因治疗、疫苗开发，甚至增强农业生物技术。该领域重点支持生物技术公司、研究机构和製药公司等最终用户。影响市场成长的关键因素包括基因工程技术的进步、生物技术研究资金的增加以及促进创新治疗方法快速推出的监管核准。可扩展的製造流程以及生物技术公司和受託製造厂商(CMO) 之间的合作有很多机会，特别是在个人化医疗领域。挑战包括高製造成本、严格的法律规范以及大规模基因治疗製造的复杂性。围绕基因改造的潜在安全问题和伦理考量也产生了限制。儘管有这些挑战，但仍有一些领域有利于创新，特别是在流程最佳化和自动化方面，以降低成本并提高效率。对 CRISPR 技术和次世代定序仪的投资也可以突破基因治疗的极限。此外，建立强大的供应链框架可以显着缓解生产瓶颈。市场的动态本质以快速的技术进步和法规环境为特征，为寻求利用尖端治疗方法的相关人员带来了挑战和机会。在应对复杂的监管环境的同时负责任地拥抱这些创新将是这个快速发展的行业实现持续增长和有影响力的突破的关键。

主要市场统计
基准年[2023] 15亿美元
预测年份 [2024] 18.8亿美元
预测年份 [2030] 73.2亿美元
复合年增长率（%） 25.34%

市场动态：快速发展的病毒载体和质体DNA 製造市场的关键市场洞察

供需的动态交互作用正在改变病毒载体和质体DNA 製造市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球基因治疗临床试验增加
    • 分子生物学技术的进展
  • 市场限制因素
    • 病毒载体和质体DNA 解决方案的製造成本较高
  • 市场机会
    • 越来越多地引入新型病毒载体和质体DNA 解决方案
    • 增加对个人化医疗的投资
  • 市场挑战
    • 对基因治疗产品安全性和有效性的担忧

波特五力：引领病毒载体与质体DNA 製造市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解病毒载体和质体DNA製造市场的外部影响

外部宏观环境因素在塑造病毒载体质体DNA 製造市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解病毒载体/质体DNA 製造市场的竞争状况

病毒载体质体DNA 製造市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵病毒载体与质体DNA製造市场供应商的绩效评估

FPNV定位矩阵是评估病毒载体和质体DNA製造市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分了供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球基因治疗临床试验数量增加
      • 分子生物学技术的进展
    • 抑制因素
      • 病毒载体和质体DNA 解决方案的製造成本较高
    • 机会
      • 更多关于新型病毒载体和质体DNA 解决方案的介绍
      • 增加对个人化医疗的投资
    • 任务
      • 对基因治疗产品安全性和有效性的担忧
  • 市场区隔分析
    • 细胞株：在受控实验室环境中增加体外细胞株的使用
    • 类型：对质体DNA 製造的需求不断增加，以将遗传物质传递给细胞
    • 转染：稳定转染在基因治疗和药物开发中日益普及
    • 最终用户：在製药和生物製药公司中扩大病毒载体和质体DNA 的潜力，用于下一代疫苗的开发和製造
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化

第六章病毒载体/质体DNA 製造市场：依类型

  • 质体DNA
  • 病毒载体
    • 腺结合病毒
    • 腺病毒
    • 慢病毒

第 7 章 依细胞株的病毒载体/质体DNA 製造市场

  • 试管内
  • 体内

第八章转染病毒载体/质体DNA製造市场

  • 稳定转染
  • 瞬时转染

第九章依适应症分类的病毒载体/质体DNA製造市场

  • 癌症
  • 遗传疾病
  • 感染疾病

第 10 章病毒载体/质体DNA 製造市场：依工作流程

  • 下游加工
    • 填充完成
    • 精製
  • 上游加工
    • 向量放大和扩展
    • 载体收集/收穫

第十一章病毒载体/质体DNA 製造市场：依应用分类

  • 细胞疗法
  • 基因治疗
  • 疫苗学

第十二章病毒载体/质体DNA 製造市场：依最终用户分类

  • 製药和生物製药公司
  • 调查机构

第十三章北美和南美的病毒载体和质体DNA製造市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第14章亚太地区病毒载体及质体DNA製造市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十五章欧洲、中东和非洲的病毒载体和质体DNA製造市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Ajinomoto Co., Inc.以6.2亿美元收购Forge Biologics
    • Genezen 获得 1,850 万美元的成长资本，以扩大病毒载体的开发和製造能力
    • CCRM 与 Membio 合作，简化细胞和基因治疗病毒载体的生产

公司名单

  • Charles River Laboratories International, Inc.
  • GE HealthCare Technologies, Inc.
  • Biovian Oy
  • c-LEcta GmbH
  • Batavia Biosciences BV
  • Thermo Fisher Scientific Inc.
  • Takara Bio Inc.
  • Avid Bioservices, Inc.
  • Wuxi AppTec Co., Ltd.
  • PerkinElmer Inc.
  • REGENXBIO Inc.
  • Lonza Group Ltd.
  • Advanced BioScience Laboratories, Inc.
  • Miltenyi Biotec BV & Co. KG
  • Genezen Laboratories, Inc.
  • FILTROX AG
  • Genezen
  • Merck KGaA
  • Akron Biotech
  • uniQure NV
  • Kaneka Eurogentec SA
  • BioNTech IMFS GmbH
  • Creative Biogene
  • Forge Biologics By Ajinomoto Co., Inc.
  • Spark Therapeutics, Inc.
  • FUJIFILM Diosynth Biotechnologies Inc.
  • GeneOne Life Science, Inc.
Product Code: MRR-030298DFFC33

The Viral Vector & Plasmid DNA Manufacturing Market was valued at USD 1.50 billion in 2023, expected to reach USD 1.88 billion in 2024, and is projected to grow at a CAGR of 25.34%, to USD 7.32 billion by 2030.

The viral vector and plasmid DNA manufacturing sector plays a pivotal role in biopharmaceuticals, driven by the increasing demand for gene therapies, vaccines, and cell therapies. It encompasses the production of viral vectors, which are tools for delivering genetic material into cells, and plasmid DNA, which serves as a template for gene therapy and DNA vaccine production. Such manufacturing is essential due to the rise in genetic disorders, cancer therapies, and the recent spotlight on vaccine development, particularly in the wake of COVID-19. Applications span across gene therapy, vaccine development, and even in enhancing agricultural biotechnologies. The sector prominently supports end-users such as biotech companies, research institutes, and pharmaceutical firms. Key factors influencing market growth include advancements in genetic engineering techniques, increased funding for biotech research, and regulatory approvals facilitating the faster introduction of innovative therapies. Opportunities abound in scalable manufacturing processes and collaboration between biotech companies and Contract Manufacturing Organizations (CMOs), especially for personalized medicine. Challenges include high production costs, stringent regulatory frameworks, and complexity in large-scale gene therapy production. Limitations also arise from potential safety concerns and ethical considerations surrounding genetic modifications. Despite these challenges, there are lucrative areas for innovation, notably in process optimization and automation to reduce costs and improve efficiency. Investment in CRISPR technology and next-gen sequencing can also push the boundary of what's achievable in genetic therapy. Moreover, developing robust supply chain frameworks can significantly alleviate production bottlenecks. The market's dynamic nature, characterized by rapid technological advancements and regulatory environments, presents both a challenge and an opportunity for stakeholders looking to leverage cutting-edge therapies. Embracing these innovations responsibly while navigating the intricate regulatory landscape will be key for sustained growth and impactful breakthroughs in this rapidly evolving industry.

KEY MARKET STATISTICS
Base Year [2023] USD 1.50 billion
Estimated Year [2024] USD 1.88 billion
Forecast Year [2030] USD 7.32 billion
CAGR (%) 25.34%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Viral Vector & Plasmid DNA Manufacturing Market

The Viral Vector & Plasmid DNA Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing number of gene therapy clinical trials worldwide
    • Growing advancement in molecular biology technologies
  • Market Restraints
    • High cost of manufacturing of viral vector & plasmid DNA solutions
  • Market Opportunities
    • Growing introduction of novel viral vector & plasmid DNA solutions
    • Rising investment in personalized medicine
  • Market Challenges
    • Concerns regarding the safety and efficacy of gene therapy products

Porter's Five Forces: A Strategic Tool for Navigating the Viral Vector & Plasmid DNA Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Viral Vector & Plasmid DNA Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Viral Vector & Plasmid DNA Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Viral Vector & Plasmid DNA Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Viral Vector & Plasmid DNA Manufacturing Market

A detailed market share analysis in the Viral Vector & Plasmid DNA Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Viral Vector & Plasmid DNA Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Viral Vector & Plasmid DNA Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Viral Vector & Plasmid DNA Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Charles River Laboratories International, Inc., GE HealthCare Technologies, Inc., Biovian Oy, c-LEcta GmbH, Batavia Biosciences B.V., Thermo Fisher Scientific Inc., Takara Bio Inc., Avid Bioservices, Inc., Wuxi AppTec Co., Ltd., PerkinElmer Inc., REGENXBIO Inc., Lonza Group Ltd., Advanced BioScience Laboratories, Inc., Miltenyi Biotec B.V. & Co. KG, Genezen Laboratories, Inc., FILTROX AG, Genezen, Merck KGaA, Akron Biotech, uniQure N.V., Kaneka Eurogentec S.A., BioNTech IMFS GmbH, Creative Biogene, Forge Biologics By Ajinomoto Co., Inc., Spark Therapeutics, Inc., FUJIFILM Diosynth Biotechnologies Inc., and GeneOne Life Science, Inc..

Market Segmentation & Coverage

This research report categorizes the Viral Vector & Plasmid DNA Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Plasmid DNA and Viral Vector. The Viral Vector is further studied across Adeno-Associated Virus, Adenovirus, and Lentivirus.
  • Based on Cell Line, market is studied across In-vitro and In-Vivo.
  • Based on Transfection, market is studied across Stable Transfection and Transient Transfection.
  • Based on Indication, market is studied across Cancer, Genetic Disorder, and Infectious Disease.
  • Based on Workflow, market is studied across Downstream Processing and Upstream Processing. The Downstream Processing is further studied across Fill-finish and Purification. The Upstream Processing is further studied across Vector Amplification & Expansion and Vector Recovery/Harvesting.
  • Based on Application, market is studied across Cell Therapy, Gene Therapy, and Vaccinology.
  • Based on End User, market is studied across Pharmaceutical & Biopharmaceutical Companies and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing number of gene therapy clinical trials worldwide
      • 5.1.1.2. Growing advancement in molecular biology technologies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of manufacturing of viral vector & plasmid DNA solutions
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing introduction of novel viral vector & plasmid DNA solutions
      • 5.1.3.2. Rising investment in personalized medicine
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns regarding the safety and efficacy of gene therapy products
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Cell Line: Growing usage of in-vitro cell lines in controlled laboratory environments
    • 5.2.2. Type: Increasing need for plasmid DNA manufacturing to deliver genetic material into cells
    • 5.2.3. Transfection: Rising popularity of stable transfection for gene therapy and drug development
    • 5.2.4. End User: Expanding the potential of viral vectors & plasmid DNA across pharmaceutical & biopharmaceutical companies for the development and production of next-generation vaccines
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Viral Vector & Plasmid DNA Manufacturing Market, by Type

  • 6.1. Introduction
  • 6.2. Plasmid DNA
  • 6.3. Viral Vector
    • 6.3.1. Adeno-Associated Virus
    • 6.3.2. Adenovirus
    • 6.3.3. Lentivirus

7. Viral Vector & Plasmid DNA Manufacturing Market, by Cell Line

  • 7.1. Introduction
  • 7.2. In-vitro
  • 7.3. In-Vivo

8. Viral Vector & Plasmid DNA Manufacturing Market, by Transfection

  • 8.1. Introduction
  • 8.2. Stable Transfection
  • 8.3. Transient Transfection

9. Viral Vector & Plasmid DNA Manufacturing Market, by Indication

  • 9.1. Introduction
  • 9.2. Cancer
  • 9.3. Genetic Disorder
  • 9.4. Infectious Disease

10. Viral Vector & Plasmid DNA Manufacturing Market, by Workflow

  • 10.1. Introduction
  • 10.2. Downstream Processing
    • 10.2.1. Fill-finish
    • 10.2.2. Purification
  • 10.3. Upstream Processing
    • 10.3.1. Vector Amplification & Expansion
    • 10.3.2. Vector Recovery/Harvesting

11. Viral Vector & Plasmid DNA Manufacturing Market, by Application

  • 11.1. Introduction
  • 11.2. Cell Therapy
  • 11.3. Gene Therapy
  • 11.4. Vaccinology

12. Viral Vector & Plasmid DNA Manufacturing Market, by End User

  • 12.1. Introduction
  • 12.2. Pharmaceutical & Biopharmaceutical Companies
  • 12.3. Research Institutes

13. Americas Viral Vector & Plasmid DNA Manufacturing Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Ajinomoto Co., Inc. to Acquire Forge Biologics for USD 620 Million
    • 16.3.2. Genezen Secures USD 18.5 Million in Growth Equity to Expand Viral Vector Development and Manufacturing Capabilities
    • 16.3.3. CCRM Partners with Membio to Streamline Production of Viral Vectors for Cell and Gene Therapies

Companies Mentioned

  • 1. Charles River Laboratories International, Inc.
  • 2. GE HealthCare Technologies, Inc.
  • 3. Biovian Oy
  • 4. c-LEcta GmbH
  • 5. Batavia Biosciences B.V.
  • 6. Thermo Fisher Scientific Inc.
  • 7. Takara Bio Inc.
  • 8. Avid Bioservices, Inc.
  • 9. Wuxi AppTec Co., Ltd.
  • 10. PerkinElmer Inc.
  • 11. REGENXBIO Inc.
  • 12. Lonza Group Ltd.
  • 13. Advanced BioScience Laboratories, Inc.
  • 14. Miltenyi Biotec B.V. & Co. KG
  • 15. Genezen Laboratories, Inc.
  • 16. FILTROX AG
  • 17. Genezen
  • 18. Merck KGaA
  • 19. Akron Biotech
  • 20. uniQure N.V.
  • 21. Kaneka Eurogentec S.A.
  • 22. BioNTech IMFS GmbH
  • 23. Creative Biogene
  • 24. Forge Biologics By Ajinomoto Co., Inc.
  • 25. Spark Therapeutics, Inc.
  • 26. FUJIFILM Diosynth Biotechnologies Inc.
  • 27. GeneOne Life Science, Inc.

LIST OF FIGURES

  • FIGURE 1. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STABLE TRANSFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSIENT TRANSFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GENETIC DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FILL-FINISH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VECTOR AMPLIFICATION & EXPANSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VECTOR RECOVERY/HARVESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VACCINOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 156. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 165. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 166. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 175. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 176. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 185. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 186. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 187. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 195. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 196. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 205. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 206. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 207. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 208. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 215. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 216. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 217. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 218. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 225. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 226. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 227. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 244. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 246. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 247. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 248. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 249. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 254. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 256. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 257. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 258. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 259. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 264. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 266. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 267. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 268. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 269. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 276. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 277. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 278. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 279. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 284. GERMANY VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. GERMANY VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD